<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 1999
Commission file number 0-28092
Medical Information Technology, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Massachusetts
(State or Other Jurisdiction of Incorporation or Organization)
04-2455639
(I.R.S. Employer Identification No.)
Meditech Circle, Westwood, MA
(Address of Principal Executive Offices)
02090
(Zip Code)
781-821-3000
(Registrant's Telephone Number)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
The number of shares of Common Stock, $.25 par value, outstanding at December
31, 1999 was 16,457,286
<PAGE> 2
Index to Form 10-K
Part I
Item 1 - Business Page 3
Item 2 - Properties Page 5
Item 3 - Legal Proceedings Page 6
Item 4 - Submission of Matters to a Vote of Security Holders Page 6
Part II
Item 5 - Market for Registrant's Common Equity and Related
Stockholder Matters Page 6
Item 6 - Selected Financial Data Page 6
Item 7 - Management's Discussion and Analysis of Financial
Condition and Results of Operations Page 7
Item 8 - Financial Statements and Supplementary Data Page 8
Item 9 - Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure Page 8
Part III
Item 10 - Directors and Executive Officers of the Registrant Page 8
Item 11 - Executive Compensation Page 10
Item 12 - Security Ownership of Certain Beneficial Owners
and Management Page 11
Item 13 - Certain Relationships and Related Transactions Page 11
Part IV
Item 14 - Exhibits, Financial Statement Schedules, and Reports
on Form 8-K Page 12
Signatures Page 12
<PAGE> 3
Part I
Item 1 - Business
COMPANY OVERVIEW
Medical Information Technology, Inc. (MEDITECH) was founded in 1969 to develop
and market information system software for the hospital industry. During 1999
combined product and service revenue reached $225 million. By the year's end
MEDITECH had more than 1,900 employees, almost 1,600 active hospital customers
throughout the U.S., Canada and the U.K., as well as a backlog of almost 100
hospitals waiting implementation.
HOSPITAL SOFTWARE
Initially MEDITECH developed a software product to automate one of the main
hospital departments, the clinical laboratory that performs various diagnostic
tests on blood and urine specimens. Within a few years, this product became
standardized, thereby requiring minimal adaptation to meet the individual needs
of a typical customer. MEDITECH extended the concept and developed additional
software products for the rest of a hospital's clinical departments.
Eventually, it moved into the financial area by developing a hospital billing
and accounts receivable product as well as various general accounting products.
Although the individual products could be operated in a stand alone fashion, a
hospital achieved maximum effectiveness when they were used in an integrated
mode, sharing access to the common clinical and financial records of the
hospital. This concept ultimately led to MEDITECH developing the so-called
hospital information system, a cohesive set of software products designed from
the onset to work in conjunction with the overall operation of the hospital and
to minimize the need for specialized interfaces.
COMPUTER HARDWARE
Software requires extensive computer and communication equipment to function.
In spite of this, MEDITECH continues to be a pure software company, limiting
itself to specifying the aggregate components needed as well as suggesting
typical configurations from certain hardware vendors. The responsibility is
left to the hospital to purchase the requisite hardware and secure a continuing
source of maintenance service for it.
The hardware components traditionally consist of a small set of central medium-
sized computers and a large set of display terminals and printers distributed
throughout the hospital. All of these elements are interconnected by means of
a standard high speed communication network. The computers execute the
software and include large disk subsystems containing the permanent and common
clinical and financial records of the hospital.
Hardware technology evolves rapidly, and the current trend is to replace the
display terminals with desktop and handheld computers, thereby forming a client
server network. In this mode of operation, the central computers become the
file servers while software is executed locally on the client computer which
makes file requests to the servers.
LICENSED SOFTWARE
MEDITECH requires a customer to sign a standard software license agreement
prior to product delivery, implementation and subsequent service of the
software. This agreement specifies a front end product fee and a front end
implementation fee both of which are payable over the implementation process,
and a monthly service fee after the site goes live. In addition to precluding
ownership and restricting transfer, the license mandates the hospital hold
MEDITECH harmless from any liability arising from incorrect operation of the
software.
MEDITECH bases its product fee on the total number of hospital beds that a
customer operates at all of its sites, and sets its implementation fee on the
total number of sites. Large hospitals pay more than small hospitals, but
incremental fees continue to diminish. The monthly service fees are always
1% of the product fees. A typical 250 bed acute care hospital might incur a
$500,000 product fee, $100,000 implementation fee and a $5,000 monthly service
fee. An order is booked and goes into the backlog when a signed software
license and 10% of both front end fees are received.
STAFF ORGANIZATION
MEDITECH is organized into functional units grouped around product development,
sales and marketing, implementation, customer service, accounting and facility
operations. All MEDITECH staff work in five company owned facilities in the
greater Boston area.
From its inception, MEDITECH utilized communication technology which allowed
much of its business activities to be performed by remote access. MEDITECH
staff sitting at their desks may access client hospitals, both personnel and
computers. The need for remote offices is thereby negated. Although most
customer contact is through the phone, certain of the sales and implementation
staff travel to customer sites.
PRODUCT DEVELOPMENT
Most of the product development staff is working on the incremental evolution
of the current product line, as well as creating a few more new products each
year. The rest of the staff is developing a set of replacement products
utilizing a new technology. Approximately every seven years, Meditech
introduces the next generation of products based on the new technology and
gradually updates existing customers.
SALES AND MARKETING
Most of the direct sales staff, organized into regions, concentrate on new
prospects. In addition, some of the sales staff monitor existing customers to
expose them to Meditech's entire product line. Marketing activities and
promotion are low key because hospitals are easily identified, finite in number
and generally send an RFP to vendors when they are contemplating the purchase
of a hospital information system.
During the sales process, prospects generally visit MEDITECH to talk to product
specialists and to view product demonstrations. Thereafter they are encouraged
to visit various MEDITECH customer sites to observe first hand the software in
actual operation and to discuss issues of concern with hospital personnel.
IMPLEMENTATION PROCESS
To ensure a successful implementation, the staff must properly train a core
group of hospital personnel about the operation of the software and how to use
it in their daily activity. To preclude interruptions from normal hospital
activities, MEDITECH mandates that the hospital personnel come to Boston for
intensive training sessions.
As training proceeds, the implementation staff will customize certain
dictionaries to fit the specific need of the hospital's environment, provide
interfaces to non-MEDITECH systems and to assist the hospital in converting
data from legacy systems. In addition, the licensed software will be
delivered, installed and tested on the customer's hardware. MEDITECH will
utilize remote access communication technology to minimize or eliminate the
need to travel.
CUSTOMER SERVICE
Once a hospital goes live, the responsibility of maintaining the customer is
transferred to the service staff. MEDITECH provides 24 hour a day service
coverage to these customers in order to respond to problem calls. In addition,
the staff updates customers with new releases of the software products as they
become available. To ensure the continuing education of the hospital staff,
MEDITECH runs seminars on the use of its products.
COLUMBIA HEALTH CARE
Columbia/HCA owns or operates over 300 hospitals in the U.S., Canada, and the
U.K. and has been MEDITECH's largest customer for some time now. By the end
of 1998 MEDITECH had completed implementation of clinical systems at all of
their hospitals. They represented 17% of MEDITECH revenues in 1998 and 9% of
MEDITECH revenues in 1999.
ITEM 2 - Properties
As of December 31, 1999 the Company owned five facilities containing about
1.1 million square feet of space, all being well maintained Class A properties
in the greater Boston area. The Company occupies 60% of the space and the
remaining 40% is leased to various tenants. The Company has adequate space
for its reasonable needs over the next few years.
<PAGE> 6
ITEM 3 - Legal Proceedings
There are no material pending legal proceedings against the Company, nor were
any initiated during the year 1999.
ITEM 4 - Submission of Matters to a Vote of Security Holders
None.
PART II
ITEM 5 - Market for Registrant's Common Equity and Related
Stockholder Matters
No trading market exists for the Company's Common Stock, and accordingly no
high and low bid information or quotations are available with respect to the
Company's Common Stock.
The Company's Common Stock is subject to right of first refusal restrictions
upon sale, assignment, transfer, pledge or other disposition of any of its
shares.
At December 31, 1999 there were 838 holders of record of its Common Stock and
16,457,286 shares outstanding.
The Company has paid quarterly cash dividends continuously since 1980.
Dividends paid per share in the last five years is set forth under Item 6.
ITEM 6 - Selected Financial Data
<TABLE>
For the Five Years Ended December 31, 1999 (in thousands where applicable):
<CAPTION>
1995 1996 1997 1998 1999
<S> <C> <C> <C> <C> <C>
Operations:
Total revenue $143,721 $167,884 $193,805 $203,813 $225,630
Operating income 58,513 69,550 78,286 79,583 91,553
Net profit 37,085 44,350 50,284 53,281 59,956
Average shares 15,782 15,863 16,029 16,203 16,392
Earnings per share $2.35 $2.80 $3.14 $3.29 $3.66
Financial Position:
Total assets 197,998 218,339 263,108 266,600 288,278
Total liabilities 60,170 55,871 73,577 49,328 41,583
Shareholders' equity 137,828 162,468 189,531 217,272 246,695
Shares outstanding 15,831 15,938 16,087 16,266 16,457
Book value per share $8.71 $10.19 $11.78 $13.36 $14.99
Other Data:
Working capital $47,573 $60,373 $44,911 $59,032 $92,130
Cash flow from operations 41,443 56,413 62,195 59,788 74,158
Depreciation 4,809 6,155 9,084 10,078 7,900
Cash dividends per share $1.24 $1.40 $1.68 $1.88 $2.00
</TABLE>
<PAGE> 7
ITEM 7 - Management's Discussion and Analysis of Financial
Condition and Results of Operations
Comparison of Fiscal Years ended December 31, 1998 and 1999:
Total revenue increased 11% from $203.8 million in 1998 to $225.6 million in
1999 as a result of increased services provided to both existing and new
customers. Operating expenses increased 8% from $124.2 million in 1998 to
$134.1 million in 1999 due primarily to higher staffing costs associated with
producing increased revenues. Operating expenses did not grow at the same pace
as revenues due to a disproportionate decrease in depreciation expense in 1999.
Additional depreciation expenses of $3.4 million were absorbed In 1997 and 1998
as a result of one-time adjustments made to unify the varying depreciation
methods in use for book versus tax calculation purposes. As a result, 1999's
depreciation expense dropped by $2.0 million and 1999 operating income
increased 15% from $79.6 million in 1998 to $91.5 million in 1999.
Other income, net of other expense, increased from $8.5 million in 1998 to $8.6
million in 1999. Two significant component changes offset each other during
the year. Interest expense decreased $1.6 million year to year as outstanding
bank debt was paid-down but 1998's results included a gain of $1.4 million
from the redemption and sale of marketable securities while there were no such
gains in 1999.
The Company's effective tax rate remained unchanged at 40% in 1999.
Comparison of Fiscal Years Ended December 31, 1997 and 1998:
1998 Revenue increased 5% to $203.8 million, while 1998 Operating Income
increased only 2% to $79.6 million. During the year the Company experienced a
decrease in the product revenue attributable to a decline in implementations
for Columbia/HCA. Staff size was not reduced in response as new orders
requiring future implementations increased significantly during the second half
of the year. The result of this caused growth in Operating Expenses to exceed
growth in Revenue. 1998 Operating Expenses increased 8% to $124.2M due to a 6%
increase in staff size and a continued moderate increase in employee salaries.
Other Income, net of Other Expense, increased from $6.4 million in 1997 to $8.5
million in 1998 due primarily to an increase of $0.9 million in rental income
and a gain of $1.4 million on redemptions and sales of marketable securities.
The Company's effective tax rate decreased from 41% in 1997 to 40% in 1998.
<PAGE> 8
ITEM 8 - Financial Statements and Supplementary Data
The Financial Statements are included as part of Exhibit 13 (Annual Report to
Shareholders)
<TABLE>
OPERATING RESULTS BY QUARTER:
For the Two Years Ended December 31, 1999 (in thousands where applicable):
<CAPTION>
Mar 31 Jun 30 Sep 30 Dec 31
<S> <C> <C> <C> <C>
1998
Total revenue $48,493 $48,933 $49,922 $56,465
Operating income 18,756 18,719 18,855 23,253
Net profit 12,137 12,353 12,387 16,404
Earnings per share $.75 $.76 $.77 $1.01
1999
Total revenue $54,456 $57,366 $56,472 $57,334
Operating income 21,709 23,496 23,020 23,328
Net profit 13,915 15,354 15,272 15,415
Earnings per share $.85 $.94 $.93 $.94
</TABLE>
ITEM 9 - Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure
None.
PART III
ITEM 10 - Directors and Executive Officers of the Registrant
The positions held by each Director and Officer of the Company are shown below.
There are no family relationships among the following persons.
Name of Director or Officer Age Position with the Company
A. Neil Pappalardo 57 Chief Executive Officer, Chairman of
the Board and Director
Lawrence A. Polimeno 58 Chief Operating Officer, President and
Director
Roland L. Driscoll 70 Director
Jerome H. Grossman 60 Director
Edward B. Roberts 64 Director
Morton E. Ruderman 63 Director
L.P. Dan Valente 69 Director
Howard Messing 47 Executive Vice President
Barbara A. Manzolillo 47 Chief Financial Officer, Treasurer and
Assistant Clerk
Roberta E. Grigg 56 Senior Vice President
Edward G. Pisinski 56 Senior Vice President
Christopher J. Anschuetz 47 Vice President
Robert S. Gale 53 Vice President
Steven B. Koretz 47 Vice President
Stuart N. Lefthes 46 Vice President
Joanne Wood 46 Vice President
Jane E. Currier 47 Chief Corporate Counsel and Clerk
<PAGE> 9
All Directors are elected each year at the annual meeting of shareholders. All
Officers are elected at the first meeting of the Board following the annual
meeting of shareholders and hold office for one year. The Board of Directors
has an Audit Committee, an Executive Compensation Committee, and a Charitable
Contribution Committee.
The following is a description of the business experience during the past five
years of each Director and Officer.
A. Neil Pappalardo, founder of the Company, is the Chief Executive Officer and
Chairman of the Board, and has been a Director since 1969.
Lawrence A. Polimeno, the President and Chief Operating Officer, has been a
Director since 1985, and has been with the Company since 1969.
Roland L. Driscoll, retired Chief Financial Officer of the Company, has been
a Director since 1985.
Jerome H. Grossman, Chief Executive Officer of Lion Gate Management Corp., has
been a Director since 1970.
Edward B. Roberts, Professor at Sloan School, Massachusetts Institute of
Technology, has been a Director since 1969.
Morton E. Ruderman, Chief Executive Officer of CRES Development, has been a
Director since 1969.
L.P. Dan Valente, Chief Executive Officer of Palomar Medical Technologies,
Inc., has been a Director since 1972.
Howard Messing has been the Executive Vice President since 1995, was a Vice
President prior to that, and has been with the Company since 1974.
Barbara A. Manzolillo has been the Chief Financial Officer since 1996, was
the Treasurer prior to that, and has been with the Company since 1975.
Roberta E. Grigg has been a Senior Vice President since 1997, was a Vice
President prior to that, and has been with the Company since 1975.
Edward G. Pisinski has been a Senior Vice President since 1997, was a Vice
President prior to that, and has been with the Company since 1973.
Christopher J. Anschuetz has been a Vice President since 1995, was a Senior
Manager prior to that, and has been with the Company since 1975.
Robert S. Gale has been a Vice President since 1995, was a Senior Manager
prior to that, and has been with the Company since 1976.
Steven B. Koretz has been a Vice President since 1997, was a Senior Manager
prior to that, and has been with the company since 1982.
Stuart N. Lefthes has been a Vice President since 1997, was a Senior Manager
prior to that, and has been with the company since 1983.
Joanne Wood has been a Vice President since 1995, was a Senior Manager prior
to that, and has been with the Company since 1983.
Jane E. Currier has been the Chief Corporate Counsel and the Clerk since
1986, and has been with the Company since 1983.
<PAGE> 10
There were no failures to file or late filings under Section 16(a)
ITEM 11 - Executive Compensation
The following table sets forth the compensation received by the Company's Chief
Executive Officer and the four most highly compensated other Officers for the
three fiscal years ended December 31, 1997, 1998 and 1999.
SUMMARY COMPENSATION TABLE
Name and Position Year Salary Bonus Other
A. Neil Pappalardo 1999 $360,000 $800,455 0
Chairman and Chief 1998 360,000 725,345 0
Executive Officer 1997 360,000 727,676 0
Lawrence A. Polimeno 1999 $240,000 $675,455 $5,811
President and Chief 1998 240,000 625,345 5,816
Operating Officer 1997 240,000 627,676 6,042
Howard Messing 1999 $216,000 $425,455 $5,811
Executive Vice President 1998 180,000 375,345 5,816
1997 180,000 377,676 6,042
Edward G. Pisinski 1999 $192,000 $325,455 $5,811
Senior Vice President 1998 156,000 300,345 5,816
Sales and Marketing 1997 156,000 302,676 6,042
Barbara A. Manzolillo 1999 $180,000 $275,455 $5,811
Chief Financial Officer 1998 144,000 225,345 5,816
and Treasurer 1997 144,000 227,676 6,042
Compensation of Executive Officers: There are no employment contracts or
agreements in effect for any officer of the Company. The Board of Directors
annually sets the total amount to be allocated in the General Bonus Program
instituted for the recognition of services rendered by all officers and
employees. In addition, the Board of Directors annually sets the total amount
to be allocated in the Officer Bonus Program instituted for the recognition
of services rendered exclusively by the officers. Finally, the Executive
Compensation Committee, composed of Mr. Roberts and Mr. Ruderman, sets Mr.
Pappalardo's annual salary and individual bonus.
Pension Plan: The Company maintains a qualified defined contribution plan for
all employees known as the Medical Information Technology, Inc. Profit Sharing
Plan. All employees of the Company who have completed one year of service
participate in the Plan. The Board of Directors sets the annual contribution
which is allocated in proportion to total compensation (capped at $100,000) of
all eligible members for the Plan year. No allocation is allowable under this
Plan to owners of 10% or more of the Company's common stock. Contributions by
members are not permitted. Benefits under the plan become fully vested after
five years of continuous service with the Company. Lump sum cash payment is
made upon retirement, death, disability, financial hardship or termination of
employment.
Compensation of Directors: The members of the Board of Directors who are not
Officers of the Company currently receive a fee of $7,000 for each fully
attended quarterly meeting, with such fee being deemed to also cover any
incidental expenses or directorial conference or committee time expended by
such directors in behalf of the Company during the year.
<PAGE> 11
ITEM 12 - Security Ownership of Certain Beneficial Owners
and Management
The following table provides information as of December 31, 1999 with respect
to the shares of Common Stock beneficially owned by each person known by the
Company to own more than 5% of the Company's outstanding Common Stock, each
Director of the Company, each Executive Officer named in the Summary
Compensation Table and by all Directors and Officers of the Company as a
group. The number of shares beneficially owned is determined according to
rules of the Securities and Exchange Commission. Under such rules, a person's
beneficial ownership includes any shares as to which such person has sole or
shared voting power or investment power.
Number of Shares Percentage
of Common Stock of Shares of
Name Beneficially Owned Common Stock
A. Neil Pappalardo 4,335,000 26.34%
Morton E. Ruderman 2,207,919 13.42%
Curtis W. Marble 1,865,052 11.33%
Meditech Profit Sharing Trust 1,605,809 9.76%
Jerome Grossman 600,675 3.65%
Lawrence A. Polimeno 558,563 3.39%
Edward B. Roberts 360,688 2.19%
Roland L. Driscoll 264,000 1.60%
Edward G. Pisinski 147,500 <1%
Howard Messing 135,000 <1%
Barbara A. Manzolillo 90,000 <1%
L. P. Dan Valente 42,500 <1%
17 Directors and Officers as a Group 8,992,845 54.64%
The address of all Officers and Directors is in care of the Company, MEDITECH
Circle, Westwood, MA 02090.
ITEM 13 - Certain Relationships and Related Transactions
None.
<PAGE> 12
PART IV
ITEM 14 - Exhibits, Financial Statement Schedules, and Reports
on Form 8-K
Exhibit 3i (Articles of Incorporation) and Exhibit 3ii (By-Laws) are
incorporated by reference from the registration statement on Form 10 effective
April 27, 1996 and from exhibit under Item 6 on Form 10-Q for the quarter ended
June 10, 1997 (Amendment to By-Laws), File # 0-28092.
Exhibit 13 (Annual Report to Shareholders) and Exhibit 27 (Financial Data
Schedule) are appended to this document.
There were no reports filed on Form 8-K during the quarter ended December 31,
1999.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Medical Information Technology, Inc.
(Registrant)
March 14, 2000
(Date)
Barbara A. Manzolillo, Chief Financial Officer and Treasurer
(Signature)
MEDICAL INFORMATION TECHNOLOGY, INC.
Financial Statements
As of December 31, 1998 and 1999
Together with Auditors' Report
<PAGE>
MEDICAL INFORMATION TECHNOLOGY, INC
Index Page
Report of Independent Public Accountants 1
Balance Sheets as of December 31, 1998 and 1999 2
Statements of Income for the Years Ended
December 31, 1997, 1998 and 1999 3
Statements of Shareholders' Equity for the
Years Ended December 31, 1997, 1998 and 1999 4
Statements of Cash Flows for the Years Ended
December 31, 1997, 1998 and 1999 5
Notes to Financial Statements 6-11
<PAGE> 1
MEDICAL INFORMATION TECHNOLOGY, INC.
Report of Independent Public Accountants
To the Shareholders and Board of Directors of
Medical Information Technology, Inc.:
We have audited the accompanying balance sheets of Medical Information
Technology, Inc. (a Massachusetts corporation) as of December 31, 1998 and 1999,
and the related statements of income, shareholders' equity and cash flows for
each of the three years in the period ended December 31, 1999. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing standards
in the United States. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An
audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Medical Information Technology,
Inc. as of December 31, 1998 and 1999, and the results of its operations and its
cash flows for each of the three years in the period ended December 31, 1999, in
conformity with accounting principles generally accepted in the United States.
Arthur Andersen LLP
Boston, Massachusetts
February 7, 2000
<PAGE> 2
MEDICAL INFORMATION TECHNOLOGY, INC.
<TABLE>
Balance Sheets
<CAPTION>
December 31,
1998 1999
------------ ------------
<S> <C> <C>
Assets
Current Assets:
Cash and cash equivalents (Note 1) $ 10,013,957 $ 15,055,559
Marketable securities (Note 2) 67,923,022 85,101,094
Accounts receivable, less reserve of
$270,000 in 1998 and $350,000 in 1999 27,770,548 30,155,739
Prepaid expenses and other current assets 152,667 -
------------ ------------
Total current assets 105,860,194 130,312,392
------------ ------------
Property, Plant and Equipment, at cost (Note 1):
Computer equipment 9,693,702 10,360,158
Furniture and fixtures 19,976,372 21,715,196
Buildings and improvements 143,125,594 143,125,594
Land 26,603,703 26,603,703
------------ ------------
199,399,371 201,804,651
Accumulated depreciation (40,416,433) (45,466,526)
------------ ------------
158,982,938 156,338,125
------------ ------------
Investments 1,757,293 1,627,204
------------ ------------
$266,600,425 $288,277,721
============ ============
Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of note payable
to a bank (Note 5) $ 15,000,000 $ -
Accounts payable 589,511 400,762
Accrued taxes 2,642,654 2,815,954
Accrued expenses (Note 4) 16,510,518 18,411,563
Customer deposits 12,085,748 16,554,566
------------ ------------
Total current liabilities 46,828,431 38,182,845
------------ ------------
Deferred Federal and State Income Taxes (Note 7) 2,500,000 3,400,000
------------ ------------
Shareholders' Equity:
Common stock, $.25 par value,
Authorized 17,000,000 shares,
Issued and outstanding 16,265,711 shares
in 1998 and 16,457,286 in 1999 4,066,428 4,114,321
Additional paid-in capital 16,190,107 21,817,889
Unrealized loss on marketable securities - (3,450,172)
Retained earnings 197,015,459 224,212,838
------------ ------------
Total shareholders' equity 217,271,994 246,694,876
------------ ------------
$266,600,425 $288,277,721
============ ============
</TABLE>
The accompanying notes are an integral part of these financial statements.
<PAGE> 3
MEDICAL INFORMATION TECHNOLOGY, INC.
<TABLE>
Statements of Income
<CAPTION>
For the Years Ended December 31,
1997 1998 1999
------------ ------------ ------------
<S> <C> <C> <C>
Operating Revenue:
Software products $131,775,141 $133,635,527 $144,671,272
Software services 62,029,361 70,177,095 80,958,543
------------ ------------ ------------
Total operating revenue 193,804,502 203,812,622 225,629,815
------------ ------------ ------------
Costs and Expenses:
Operating and product development 74,666,248 81,046,899 88,172,360
Selling, general and administrative 40,852,721 43,182,408 45,904,831
------------ ------------ ------------
Total costs and expenses 115,518,969 124,229,307 134,077,191
------------ ------------ ------------
Income from operations 78,285,533 79,583,315 91,552,624
Dividend, Interest and Other Income 12,236,282 16,723,587 15,680,034
Interest and Other Expense 5,879,160 8,228,173 7,079,322
------------ ------------ ------------
Income before provision
for income taxes 84,642,655 88,078,729 100,153,336
Provision for Income Taxes (Note 7):
State 6,343,141 7,795,428 8,564,840
Federal 28,015,459 27,002,343 31,632,332
------------ ------------ ------------
Net income $ 50,284,055 $ 53,280,958 $ 59,956,164
============ ============ ============
Basic and Diluted Net Income
per Share $ 3.14 $ 3.29 $ 3.66
============ ============ ============
Shares Used in Computing Basic and
Diluted Net Income per Share 16,029,071 16,202,628 16,392,024
============ ============ ============
</TABLE>
The accompanying notes are an integral part of these financial statements.
<PAGE> 4
MEDICAL INFORMATION TECHNOLOGY, INC.
<TABLE>
Statements of Shareholders' Equity
<CAPTION>
Common Stock Total
Number of Paid-in Retained Shareholders'
Shares Capital Earnings Equity
---------- ----------- ------------ ------------
<S> <C> <C> <C> <C>
Balance, December 31, 1996 15,938,365 $11,664,734 $150,803,288 $162,468,022
Sale of 108,847 shares of
common stock 108,847 2,612,328 - 2,612,328
Issuance of 40,000 shares of
common stock to qualified
profit sharing plan 40,000 1,080,000 - 1,080,000
Net income - - 50,284,055 50,284,055
Dividends - - (26,913,600) (26,913,600)
---------- ----------- ------------ ------------
Balance, December 31, 1997 16,087,212 15,357,062 174,173,743 189,530,805
Sale of 138,499 shares of
common stock 138,499 3,739,473 - 3,739,473
Issuance of 40,000 shares of
common stock to qualified
profit sharing plan 40,000 1,160,000 - 1,160,000
Net income - - 53,280,958 53,280,958
Dividends - - (30,439,242) (30,439,242)
---------- ----------- ------------ ------------
Balance, December 31, 1998 16,265,711 20,256,535 197,015,459 217,271,994
Sale of 151,575 shares of
common stock 151,575 4,395,675 - 4,395,675
Issuance of 40,000 shares of
common stock to qualified
profit sharing plan 40,000 1,280,000 - 1,280,000
Net income - - 59,956,164 59,956,164
Unrealized loss on marketable
securities - - (3,450,172) (3,450,172)
Dividends - - (32,758,785) (32,758,785)
---------- ----------- ------------ ------------
Balance, December 31, 1999 16,457,286 $25,932,210 $220,762,666 $246,694,876
========== =========== ============ ============
</TABLE>
The accompanying notes are an integral part of these financial statements.
<PAGE> 5
MEDICAL INFORMATION TECHNOLOGY, INC.
<TABLE>
Statements of Cash Flows
<CAPTION>
For the Years Ended December 31,
1997 1998 1999
----------- ----------- -----------
<S> <C> <C> <S>
Cash Flows from Operating Activities:
Net income $50,284,055 $53,280,958 $59,956,164
Adjustments to reconcile net
income to net cash provided
by operating activities
Depreciation 9,084,216 10,078,344 7,899,623
Deferred income taxes 768,337 600,000 900,000
Stock contributions to qualified
profit sharing plan 1,080,000 1,160,000 1,280,000
Gain on sale of securities, net (6,361) (1,419,291) -
Allowance for doubtful accounts 60,000 - 80,000
Changes in assets and liabilities
Accounts receivable (4,504,151) (1,510,608) (2,465,191)
Prepaid expenses and
other current assets (9,179) (53,180) 152,667
Accounts payable (142,626) (105,357) (188,747)
Accrued expenses 1,282,422 1,806,367 2,074,344
Customer deposits 4,297,963 (4,049,638) 4,468,818
----------- ----------- -----------
Net cash provided by
operating activities 62,194,676 59,787,595 74,157,676
----------- ----------- -----------
Cash Flows from Investing Activities:
Purchases of property, plant
and equipment (57,936,029) (5,092,834) (5,254,810)
Purchases of marketable securities (18,373,509) (52,312,705) (20,628,245)
Sales of marketable securities 17,173,099 48,157,854 -
Decrease in investments resulting
from distributions 59,131 294,458 130,089
----------- ----------- -----------
Net cash used in
investing activities (59,077,308) (8,953,227) (25,752,966)
----------- ----------- -----------
Cash Flows from Financing Activities:
Borrowings on note payable to a bank 43,000,000 - -
Payments of note payable to a bank (31,500,000) (22,500,000) (15,000,000)
Sale of common stock 2,612,328 3,739,473 4,395,675
Dividends paid (26,913,600) (30,439,242) (32,758,785)
----------- ----------- -----------
Net cash used in
financing activities (12,801,272) (49,199,769) (43,363,110)
----------- ----------- -----------
Net (Decrease) Increase in Cash
and Cash Equivalents (9,683,904) 1,634,599 5,041,602
Cash and Cash Equivalents,
beginning of year 18,063,262 8,379,358 10,013,957
----------- ----------- -----------
Cash and Cash Equivalents,
end of year $ 8,379,358 $10,013,957 $15,055,559
=========== =========== ===========
Supplemental Disclosure of
Cash Flow Information:
Cash paid for Income taxes $34,482,284 $33,224,366 $39,650,335
Cash paid in Interest $ 2,394,030 $ 2,119,642 $ 470,891
Noncash item - Unrealized loss
on marketable securities $ - $ - $(3,450,172)
</TABLE>
The accompanying notes are an integral part of these financial statements.
<PAGE> 6
MEDICAL INFORMATION TECHNOLOGY, INC.
Notes to Financial Statements
December 31, 1999
(1) Operations and Accounting Policies
Medical Information Technology, Inc. (the Company) is engaged in the
development, manufacture and licensing of computer software products and related
services used in the medical field. The principal market for the Company's
products consists of health care providers primarily located in the United
States and Canada.
The accompanying financial statements reflect the application of certain
accounting policies discussed below. The preparation of financial statements in
conformity with generally accepted accounting principles requires management to
make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those estimates.
(a) Revenue Recognition
During 1998, the Company adopted the provisions of the American Institute of
Certified Public Accountants (AICPA) Statement of Position 97-2, Software
Revenue Recognition (SOP 97-2). The Company enters into software product
contracts that provide for a customer deposit upon contract execution, milestone
billings and fixed monthly service fees thereafter. As a result, SOP 97-2
requires the Company to recognize product and service revenue using the
percentage-of-completion method prescribed by SOP 81-1, Accounting for
Performance of Construction-Type and Certain Production-Type Contracts.
Accordingly, product revenue is recognized at the completion of each milestone
and service revenue, including maintenance, is recognized as services are
rendered.
(b) Software Development Costs
In accordance with Statement of Financial Accounting Standards (SFAS) No. 86,
Accounting for the Costs of Computer Software to Be Sold, Leased or Otherwise
Marketed, the Company is required to capitalize software development costs
incurred after technological feasibility of the software development projects is
established and the realizability of such capitalized costs through future
operations is expected if such costs become material. To date, all of the
Company's costs have been immaterial and as such have been charged to operations
as incurred.
<PAGE> 7
MEDICAL INFORMATION TECHNOLOGY, INC.
(c) Depreciation
The Company provides for depreciation on its property, plant and equipment in
amounts estimated to allocate the costs thereof under various depreciation
methods over the following estimated useful lives:
Description Useful Life
-------------------------- -------------
Computer equipment 3-5 years
Furniture and fixtures 7-10 years
Buildings and improvements 31.5-40 years
(d) Cash and Cash Equivalents
The Company considers all highly liquid investments purchased with original
maturities of 90 days or less to be cash equivalents.
(e) Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of
credit risk are principally cash, cash equivalents and accounts receivable. The
Company places its cash and cash equivalents in highly rated institutions.
Concentration of credit risk with respect to accounts receivable is limited to
certain customers to whom the Company makes substantial sales. To reduce risk,
the Company routinely assesses the financial strength of its customers and, as a
result, believes that its accounts receivable credit risk exposure is limited.
The Company maintains an allowance for potential credit losses but historically
has not experienced any significant credit losses related to an individual
customer or groups of customers. As of December 31, 1998, no customers
accounted for more than 10% of accounts receivable. As of December 31, 1999,
one customer accounted for 16% of accounts receivable.
(f) Net Income per Common Share
In accordance with SFAS No. 128, Earnings per Share, the Company reports both
basic and diluted earnings per share (EPS). The Company has no common stock
equivalents, thus both basic EPS and diluted EPS are computed by dividing net
income by the weighted-average number of common shares outstanding during the
year.
<PAGE> 8
MEDICAL INFORMATION TECHNOLOGY, INC.
(g) Comprehensive Income
The Company adopted SFAS No. 130, Reporting Comprehensive Income, effective
January 1, 1998. SFAS No. 130 establishes standards for reporting and display
of comprehensive income and its components in the financial statements.
Comprehensive income is the total of net income and all other nonowner changes
in equity including items such as unrealized holding gains/losses on securities
classified as available-for-sale, foreign currency translation adjustments and
minimum pension liability adjustments. The Company had no such items for the
years ended December 31, 1997 and 1998 and one such item in 1999, an unrealized
holding loss on marketable securities, totaling $3,450,172.
(h) Segment and Enterprise-Wide Reporting
In 1997, the Financial Accounting Standards Board (FASB) issued SFAS No. 131,
Disclosures about Segments of an Enterprise and Related Information. SFAS No.
131 requires certain financial and supplementary information to be disclosed on
an annual and interim basis for each reportable operating segment of an
enterprise, as defined. Based on the criteria set forth in SFAS No. 131, the
Company currently operates in one operating segment, medical software and
services.
SFAS No. 131 also requires that certain enterprise-wide disclosures be made
related to products and services, geographic areas and major customers. The
Company derives substantially all of its operating revenue from the sale and
support of one group of similar products and services. All of the Company's
assets are located within the United States. During 1997, 1998 and 1999, the
Company derived its operating revenue from the following countries (as a
percentage of total operating revenue):
1997 1998 1999
---- ---- ----
United States 86% 90% 85%
Canada 10 8 13
Other 4 2 2
---- ---- ----
100% 100% 100%
==== ==== ====
During the years ended December 31, 1997, 1998 and 1999, one customer accounted
for approximately 21%, 17% and 9% of operating revenue, respectively.
<PAGE> 9
MEDICAL INFORMATION TECHNOLOGY, INC.
(2) Marketable Securities
The Company accounts for its investments in accordance with SFAS No. 115,
Accounting for Certain Investments in Debt and Equity Securities. SFAS No. 115
requires companies to classify their short-term investments as either trading,
available-for-sale or held-to-maturity. The Company's marketable securities
consist of common and preferred equity securities and have been classified as
available-for-sale. Accordingly, they should be recorded in the financial
statements at fair market value. The fair market value of these securities was
determined based on quoted market prices. At December 31, 1998 and 1999, the
amortized cost basis and the net after tax aggregate fair value and net
unrealized holding gains (losses) are as follows:
Amortized Unrealized
Cost Gain (Loss) Fair Value
----------- ----------- -----------
December 31, 1998 - Common and
preferred equity securities $67,923,022 $ 3,886,795 $71,809,817
December 31, 1999 - Common and
preferred equity securities $88,551,266 $(3,450,172) $85,101,094
During the year ended December 31, 1998, the Company sold certain available-for-
sale securities resulting in a realized gain of $1,419,291. During the year
ended December 31, 1999, the Company did not sell any of its marketable
securities.
(3) Allowance for Doubtful Accounts
A summary of the allowance for doubtful accounts activity for the years ended
December 31, 1997, 1998 and 1999 is as follows:
1997 1998 1999
-------- -------- --------
Balance, beginning of year $210,000 $270,000 $270,000
Amounts charged to expense 66,900 9,826 81,100
Amounts written off (6,900) (9,826) (1,100)
-------- -------- --------
Balance, end of year $270,000 $270,000 $350,000
======== ======== ========
<PAGE> 10
MEDICAL INFORMATION TECHNOLOGY, INC.
(4) Accrued Expenses
Accrued expenses consist of the following at December 31, 1998 and 1999:
1998 1999
----------- -----------
Accrued bonuses $13,550,000 $15,500,000
Accrued vacation 1,650,000 1,925,000
Other 1,310,518 986,563
----------- -----------
$16,510,518 $18,411,563
=========== ===========
(5) Note Payable to a Bank
In connection with the purchase of real estate in August 1997, the Company
amended its existing loan agreement and entered into an unsecured note payable
with a bank. The amount of the note payable was $54,000,000 of which $15,000,
000 was outstanding at December 31, 1998. The note is payable in monthly
installments of $1,500,000 plus accrued interest. Interest on the outstanding
principle balance is payable at the Bank's prime rate less 1% (6.75% at December
31, 1998). In connection with this note, the Company must maintain certain
levels of net income as defined. During 1999, the Company paid the balance of
this note payable.
(6) Qualified Profit Sharing Plan
The Company has no obligation for post employment or post retirement benefits.
The Company maintains a qualified profit sharing plan that provides deferred
compensation to substantially all of its employees. Contributions to the plan
are at the discretion of the Board of Directors and may be in the form of
Company stock or cash. A summary of contributions made during the years ended
December 31, 1997, 1998 and 1999 is as follows:
1997 1998 1999
---------- ---------- ----------
Cash $2,320,000 $2,340,000 $2,720,000
Company common stock
40,000 shares at $27/share 1,080,000 - -
40,000 shares at $29/share - 1,160,000 -
40,000 shares at $32/share - - 1,280,000
---------- ---------- ----------
$3,400,000 $3,500,000 $4,000,000
========== ========== ==========
<PAGE> 11
MEDICAL INFORMATION TECHNOLOGY, INC.
(7) Income Taxes
The Company follows the provisions of SFAS No. 109, Accounting for Income Taxes.
The components of the net deferred tax liability recognized in the accompanying
balance sheets are as follows:
1998 1999
---------- ----------
Tax reserves $3,886,700 $5,350,527
Deferred revenue (618,700) (1,040,527)
Other reserves and expenses (768,000) (910,000)
---------- ----------
Total net deferred tax liability $2,500,000 $3,400,000
========== ==========
The components of the provision for income taxes shown in the accompanying
statements of income consist of the following:
1997 1998 1999
----------- ----------- -----------
State
Current $ 6,151,057 $ 7,645,428 $ 8,339,848
Deferred 192,084 150,000 225,000
----------- ----------- -----------
$ 6,343,141 $ 7,795,428 $ 8,564,840
=========== =========== ===========
Federal
Current $27,439,206 $26,552,343 $30,957,332
Deferred 576,253 450,000 675,000
----------- ----------- -----------
$28,015,459 $27,002,343 $31,632,332
=========== =========== ===========
The effective income tax rate varies from the amount computed using the
statutory U.S. income tax rate as follows:
1997 1998 1999
----- ----- -----
Statutory tax rate 35.0% 35.0% 35.0%
Increase in taxes resulting from state income
taxes, net of federal income tax benefit 4.9 5.8 5.6
Dividend income exclusion (1.4) (1.2) (1.3)
Other 2.1 (0.1) 0.8
----- ----- -----
40.6% 39.5% 40.1%
===== ===== =====
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-END> DEC-31-1999
<CASH> 15,056
<SECURITIES> 85,101
<RECEIVABLES> 28,617
<ALLOWANCES> 350
<INVENTORY> 0
<CURRENT-ASSETS> 130,313
<PP&E> 201,805
<DEPRECIATION> 45,467
<TOTAL-ASSETS> 288,278
<CURRENT-LIABILITIES> 38,183
<BONDS> 0
0
0
<COMMON> 4,114
<OTHER-SE> 242,581
<TOTAL-LIABILITY-AND-EQUITY> 288,278
<SALES> 144,671
<TOTAL-REVENUES> 225,630
<CGS> 0
<TOTAL-COSTS> 134,077
<OTHER-EXPENSES> 6,609
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 471
<INCOME-PRETAX> 100,153
<INCOME-TAX> 40,197
<INCOME-CONTINUING> 59,956
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 59,956
<EPS-BASIC> 3.66
<EPS-DILUTED> 3.66
</TABLE>
